JP5895325B2 - 薬剤溶出型医療器具の作成方法 - Google Patents
薬剤溶出型医療器具の作成方法 Download PDFInfo
- Publication number
- JP5895325B2 JP5895325B2 JP2013529177A JP2013529177A JP5895325B2 JP 5895325 B2 JP5895325 B2 JP 5895325B2 JP 2013529177 A JP2013529177 A JP 2013529177A JP 2013529177 A JP2013529177 A JP 2013529177A JP 5895325 B2 JP5895325 B2 JP 5895325B2
- Authority
- JP
- Japan
- Prior art keywords
- core member
- core
- outer member
- stent
- crown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 claims description 66
- 239000013543 active substance Substances 0.000 claims description 49
- 239000002131 composite material Substances 0.000 claims description 19
- BLIQUJLAJXRXSG-UHFFFAOYSA-N 1-benzyl-3-(trifluoromethyl)pyrrolidin-1-ium-3-carboxylate Chemical group C1C(C(=O)O)(C(F)(F)F)CCN1CC1=CC=CC=C1 BLIQUJLAJXRXSG-UHFFFAOYSA-N 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 238000004804 winding Methods 0.000 claims description 9
- 239000003146 anticoagulant agent Substances 0.000 claims description 8
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000011733 molybdenum Substances 0.000 claims description 7
- 229910052715 tantalum Inorganic materials 0.000 claims description 7
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 7
- 230000001028 anti-proliverative effect Effects 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 229940127218 antiplatelet drug Drugs 0.000 claims description 6
- 238000011049 filling Methods 0.000 claims description 6
- 229910052750 molybdenum Inorganic materials 0.000 claims description 6
- -1 antifibrin Substances 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 239000010955 niobium Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 239000003080 antimitotic agent Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 229910052732 germanium Inorganic materials 0.000 claims description 4
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052758 niobium Inorganic materials 0.000 claims description 4
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 4
- 229910052702 rhenium Inorganic materials 0.000 claims description 4
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 239000010703 silicon Substances 0.000 claims description 4
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- 239000010937 tungsten Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 238000007493 shaping process Methods 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 238000005304 joining Methods 0.000 claims description 2
- 239000004019 antithrombin Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 description 21
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 238000005530 etching Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 239000011149 active material Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960002768 dipyridamole Drugs 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 229960002930 sirolimus Drugs 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 229960003912 probucol Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 201000000054 Coronary Restenosis Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 229910000599 Cr alloy Inorganic materials 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229910001226 L605 Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229910001182 Mo alloy Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229910004529 TaF 5 Inorganic materials 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000002506 anticoagulant protein Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000003698 laser cutting Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/121—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
- A61F2002/91541—Adjacent bands are arranged out of phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91575—Adjacent bands being connected to each other connected peak to trough
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0013—Horseshoe-shaped, e.g. crescent-shaped, C-shaped, U-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0063—Three-dimensional shapes
- A61F2230/0091—Three-dimensional shapes helically-coiled or spirally-coiled, i.e. having a 2-D spiral cross-section
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
- Y10T29/49885—Assembling or joining with coating before or during assembling
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49995—Shaping one-piece blank by removing material
Description
Claims (24)
- ステントの作成方法であって、
外側部材と、該外側部材のルーメン内に配置されたコア部材とを有する細長い複合部材を利用するステップと、
前記複合部材を、クラウンにより相互接続している複数のストラットを有する波形を有するステントパターンに形作るステップと、
前記外側部材を貫通する開口部を形成するステップと、
前記複合部材を前記パターンに形作るステップの後、前記外側部材を損傷することなく前記コア部材が波形の少なくとも複数のストラットから取り除かれ、前記コア部材が波形の少なくとも複数のクラウンから取り除かれないように、複合部材を処理し、少なくとも複数のストラットにルーメンを有する外側部材と少なくとも複数のクラウンにコア部材を有する外側部材とを残すステップと、を備えている、
ことを特徴とするステントの作成方法。 - コア部材を取り除いた後に、前記ルーメンを生物学的または薬学的活性物質で満たすステップをさらに備えている、
請求項1に記載の方法。 - 前記の生物学的または薬学的活性物質が、抗腫瘍剤、抗有糸分裂剤、抗炎症、抗血小板剤、抗凝固剤、抗フィブリン、アンチトロンビン、抗増殖剤、抗生物質、抗酸化剤、および抗アレルギー物質ならびにそれらの組合せからなる群から選択される、
請求項2に記載の方法。 - 複合部材の処理ステップが、コア部材を取り除くために、前記複合部材を、他の部材と反応しないが、コア部材とは反応するエッチング剤に曝すステップを備えている、
請求項1に記載の方法。 - 前記エッチング剤は、コア部材を分解する液体化学物質である、
請求項4に記載の方法。 - 前記エッチング剤が気体である、
請求項5に記載の方法。 - 前記外側部材はMP35Nから作成され、前記コア部材はタンタル、タングステン、モリブデン、ニオブ、レニウム、炭素、ゲルマニウム、およびシリコンから作成され、エッチング剤が二ふっ化キセノンである、
請求項6に記載の方法。 - 前記コア部材が、エッチング剤に可溶性であり、前記外側部材がエッチング剤に可溶性でない、
請求項4に記載の方法。 - 前記コア部材が全てのストラットから取り除かれる、
請求項1に記載の方法。 - コア部材が任意のクラウンから取り除かれない、
請求項1に記載の方法。 - 前記コア部材が外側部材よりも放射線不透過性である、
請求項1に記載の方法。 - コア部材の一部がクラウンに残されたままルーメンがクラウンを通じて提供されるよう、コア部材が残された少なくとも複数のクラウンで、コア部材の一部を取り除くステップをさらに備えている、
請求項1に記載の方法。 - 各複合部材が、外側部材と、外側部材のルーメン内に配置された内側部材とを含む複数の細長い複合部材を利用するステップと、
各外側部材を、クラウンにより相互接続されている複数のストラットを有する波形に形作るステップと、
各波形を巻き付けて円筒状エレメントとするステップと、
前記円筒状エレメントを共通の長手方向軸線に沿って整列させ結合して管状ステントを形成するステップと、
外側部材を貫通する開口部を形成するステップと、
前記複合部材を波形に形作るステップの後に、外側部材を損傷することなく波形の少なくとも複数のストラットから内側部材が取り除かれ、コア部材が、波形の少なくとも複数のクラウンから取り除かれないように、前記複合部材を処理し、少なくとも複数のストラットにルーメンを有する外側部材と、少なくとも複数のクラウンにコア部材を有する外側部材を残ステップと、を備えている、
ことを特徴とするステントの作成方法。 - コア部材を取り除いた後に、ルーメンを生物学的または薬学的活性物質で満たすステップを備えている、
請求項13に記載の方法。 - 生物学的または薬学的活性物質が、抗腫瘍剤、抗有糸分裂剤、抗炎症、抗血小板剤、抗凝固剤、抗フィブリン、アンチトロンビン、抗増殖剤、抗生物質、抗酸化剤、および抗アレルギー物質ならびにそれらの組合せからなる群から選択される、
請求項14に記載の方法。 - 前記複合部材を処理するステップが、前記コア部材を取り除くために、外側部材とは反応しないが、コア部材とは反応するエッチング剤に前記複合部材を曝すステップを備えている、
請求項13に記載の方法。 - 前記エッチング剤が、前記コア部材を分解する液体の化学物質である、
請求項16に記載の方法。 - 前記エッチング剤が気体である、
請求項17に記載の方法。 - 前記外側部材がMP35Nから作成され、
前記コア部材は、タンタル、タングステン、モリブデン、ニオブ、レニウム、炭素、ゲルマニウム、およびシリコンから作成され、
エッチング剤が二ふっ化キセノンである、
請求項18に記載の方法。 - 前記コア部材がエッチング剤に可溶であり、前記外側部材がエッチング剤に可溶でない、
請求項16に記載の方法。 - 前記コア部材が全てのストラットから取り除かれる、
請求項13に記載の方法。 - 前記コア部材が任意のクラウンから取り除かれない、
請求項13に記載の方法。 - 前記コア部材が、外側部材よりも放射線不透過性である、
請求項13に記載の方法。 - コア部材の一部がクラウンに残されたままクラウンを通じてルーメンが提供されるよう、コア部材が残された、少なくとも複数のクラウンで、コア部材の一部を取り除くステップをさらに備えている、
請求項13に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/884,343 US8333801B2 (en) | 2010-09-17 | 2010-09-17 | Method of Forming a Drug-Eluting Medical Device |
US12/884,343 | 2010-09-17 | ||
PCT/US2011/049761 WO2012036890A1 (en) | 2010-09-17 | 2011-08-30 | Method of forming a drug-eluting medical device |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013541971A JP2013541971A (ja) | 2013-11-21 |
JP5895325B2 true JP5895325B2 (ja) | 2016-03-30 |
Family
ID=44583501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529177A Active JP5895325B2 (ja) | 2010-09-17 | 2011-08-30 | 薬剤溶出型医療器具の作成方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8333801B2 (ja) |
EP (1) | EP2616110B1 (ja) |
JP (1) | JP5895325B2 (ja) |
CN (1) | CN103249437B (ja) |
WO (1) | WO2012036890A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169178B1 (en) * | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
CN101732114B (zh) * | 2008-11-04 | 2014-07-30 | 上海微创医疗器械(集团)有限公司 | 开有载药槽的冠状动脉血管支架 |
US9060889B2 (en) * | 2009-09-18 | 2015-06-23 | Medtronic Vascular, Inc. | Methods for forming an orthogonal end on a helical stent |
US9119736B2 (en) | 2012-01-27 | 2015-09-01 | Medtronic Vascular, Inc. | Hollow drug-filled stent and method of forming hollow drug-filled stent |
US9649208B2 (en) * | 2012-04-13 | 2017-05-16 | Medtronic Vascular, Inc. | Hollow drug-filled stent and method of forming hollow drug-filled stent |
US8998977B2 (en) * | 2012-04-13 | 2015-04-07 | Medtronic Vascular, Inc. | Hollow drug-filled stent and method of forming hollow drug-filled stent |
US9549832B2 (en) | 2012-04-26 | 2017-01-24 | Medtronic Vascular, Inc. | Apparatus and methods for filling a drug eluting medical device via capillary action |
US9204982B2 (en) | 2012-04-26 | 2015-12-08 | Medtronic Vascular, Inc. | Apparatus and methods for filling a drug eluting medical device via capillary action |
US9155645B2 (en) * | 2012-06-26 | 2015-10-13 | Abbott Cardiovascular Systems Inc. | Implantable prosthesis with radiopaque particles and method of making same |
US9149375B2 (en) * | 2012-06-26 | 2015-10-06 | Abbott Cardiovascular Systems Inc. | Radiopaque drug-filled prosthesis and method of making same |
WO2014151906A1 (en) | 2013-03-14 | 2014-09-25 | Medtronic Vascular Inc. | Method for manufacturing a stent and stent manufactured thereby |
US9398966B2 (en) | 2013-03-15 | 2016-07-26 | Medtronic Vascular, Inc. | Welded stent and stent delivery system |
WO2017214434A1 (en) | 2016-06-10 | 2017-12-14 | Medtronic Vascular Inc. | Drug-eluting stent formed from a deformable hollow strut for a customizable elution rate |
US10226367B2 (en) | 2016-12-19 | 2019-03-12 | Medtronic Vascular, Inc. | Apparatus and methods for filling a drug eluting medical device via capillary action |
IL310183A (en) * | 2021-08-17 | 2024-03-01 | Medinol Ltd | A stent with an improved reduced contraction profile |
Family Cites Families (128)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2153936A (en) | 1938-05-21 | 1939-04-11 | Gulf Research Development Co | Machine for continuously forming curved wire forms |
US4531933A (en) | 1982-12-07 | 1985-07-30 | C. R. Bard, Inc. | Helical ureteral stent |
US4643716A (en) | 1984-09-26 | 1987-02-17 | The Kendall Company | Multi-size ureteral stent |
US4720384A (en) | 1985-05-03 | 1988-01-19 | E. I. Du Pont De Nemours And Company | Manufacture of hollow fine tubular drug delivery systems |
US4763647A (en) | 1987-01-06 | 1988-08-16 | C. R. Bard, Inc. | Dual coil steerable guidewire |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US4800082A (en) | 1987-03-23 | 1989-01-24 | The Dow Chemical Company | Sustained release microbiological control composition |
US4813925A (en) | 1987-04-21 | 1989-03-21 | Medical Engineering Corporation | Spiral ureteral stent |
US5154705A (en) | 1987-09-30 | 1992-10-13 | Lake Region Manufacturing Co., Inc. | Hollow lumen cable apparatus |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US5133732A (en) | 1987-10-19 | 1992-07-28 | Medtronic, Inc. | Intravascular stent |
US5782903A (en) | 1987-10-19 | 1998-07-21 | Medtronic, Inc. | Intravascular stent and method |
US4913683A (en) | 1988-07-05 | 1990-04-03 | Medical Engineering Corporation | Infusion stent system |
US5019090A (en) | 1988-09-01 | 1991-05-28 | Corvita Corporation | Radially expandable endoprosthesis and the like |
US5063935A (en) | 1989-04-27 | 1991-11-12 | C. R. Bard, Inc. | Catheter guidewire with varying radiopacity |
ATE120377T1 (de) | 1990-02-08 | 1995-04-15 | Howmedica | Aufblasbarer dilatator. |
US5345945A (en) | 1990-08-29 | 1994-09-13 | Baxter International Inc. | Dual coil guidewire with radiopaque distal tip |
DE4104702C2 (de) | 1991-02-15 | 1996-01-18 | Malte Neuss | Implantate für Organwege in Wendelform |
US5605162A (en) | 1991-10-15 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Method for using a variable stiffness guidewire |
US6497709B1 (en) | 1992-03-31 | 2002-12-24 | Boston Scientific Corporation | Metal medical device |
US7101392B2 (en) | 1992-03-31 | 2006-09-05 | Boston Scientific Corporation | Tubular medical endoprostheses |
US5306250A (en) | 1992-04-02 | 1994-04-26 | Indiana University Foundation | Method and apparatus for intravascular drug delivery |
US5630840A (en) | 1993-01-19 | 1997-05-20 | Schneider (Usa) Inc | Clad composite stent |
US5538735A (en) | 1993-02-19 | 1996-07-23 | Ahn; Sam S. | Method of making a drug delivery system using hollow fibers |
US20020055710A1 (en) | 1998-04-30 | 2002-05-09 | Ronald J. Tuch | Medical device for delivering a therapeutic agent and method of preparation |
US5716410A (en) | 1993-04-30 | 1998-02-10 | Scimed Life Systems, Inc. | Temporary stent and method of use |
US5891108A (en) | 1994-09-12 | 1999-04-06 | Cordis Corporation | Drug delivery stent |
US5569197A (en) | 1994-12-21 | 1996-10-29 | Schneider (Usa) Inc | Drug delivery guidewire |
US5843117A (en) | 1996-02-14 | 1998-12-01 | Inflow Dynamics Inc. | Implantable vascular and endoluminal stents and process of fabricating the same |
EP0801934B1 (en) | 1996-04-16 | 2000-06-14 | Medtronic, Inc. | Welded sinusoidal wave stent |
US6783543B2 (en) | 2000-06-05 | 2004-08-31 | Scimed Life Systems, Inc. | Intravascular stent with increasing coating retaining capacity |
US5670161A (en) | 1996-05-28 | 1997-09-23 | Healy; Kevin E. | Biodegradable stent |
US5733326A (en) * | 1996-05-28 | 1998-03-31 | Cordis Corporation | Composite material endoprosthesis |
CA2213015A1 (en) | 1996-08-23 | 1998-02-23 | Arterial Vascular Engineering, Inc. | A profiled stent and method of manufacture |
US5824045A (en) | 1996-10-21 | 1998-10-20 | Inflow Dynamics Inc. | Vascular and endoluminal stents |
US6099561A (en) | 1996-10-21 | 2000-08-08 | Inflow Dynamics, Inc. | Vascular and endoluminal stents with improved coatings |
ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
US5980564A (en) | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
EP0966271A1 (en) | 1997-11-06 | 1999-12-29 | Orbon Corporation | Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same |
US6022369A (en) | 1998-02-13 | 2000-02-08 | Precision Vascular Systems, Inc. | Wire device with detachable end |
US20040254635A1 (en) | 1998-03-30 | 2004-12-16 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US7208011B2 (en) | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
WO1999065623A1 (en) | 1998-06-15 | 1999-12-23 | Scimed Life Systems, Inc. | Process of making composite stents with gold alloy cores |
US6358276B1 (en) | 1998-09-30 | 2002-03-19 | Impra, Inc. | Fluid containing endoluminal stent |
US6547814B2 (en) | 1998-09-30 | 2003-04-15 | Impra, Inc. | Selective adherence of stent-graft coverings |
US6364902B1 (en) | 1998-10-05 | 2002-04-02 | Noble-Met, Ltd. | Metal composite tube for biomedical applications |
US6063101A (en) | 1998-11-20 | 2000-05-16 | Precision Vascular Systems, Inc. | Stent apparatus and method |
US6558422B1 (en) | 1999-03-26 | 2003-05-06 | University Of Washington | Structures having coated indentations |
US6478778B1 (en) | 1999-05-28 | 2002-11-12 | Precision Vascular Systems, Inc. | Apparatus for delivering fluids to blood vessels, body cavities, and the like |
EP1229901B1 (en) | 1999-11-17 | 2009-03-18 | Boston Scientific Limited | Microfabricated devices for the delivery of molecules into a carrier fluid |
EP1132058A1 (en) * | 2000-03-06 | 2001-09-12 | Advanced Laser Applications Holding S.A. | Intravascular prothesis |
US8252044B1 (en) | 2000-11-17 | 2012-08-28 | Advanced Bio Prosthestic Surfaces, Ltd. | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US20030021825A1 (en) | 2000-06-28 | 2003-01-30 | Pathak Chandrashekhar P. | Cleaning of medical devices with supercritical fluids |
US6585765B1 (en) | 2000-06-29 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Implantable device having substances impregnated therein and a method of impregnating the same |
ATE440945T1 (de) | 2000-07-07 | 2009-09-15 | Cambridge Entpr Ltd | Menschliche myelom zelllinie |
US6758859B1 (en) | 2000-10-30 | 2004-07-06 | Kenny L. Dang | Increased drug-loading and reduced stress drug delivery device |
US10398830B2 (en) | 2000-11-17 | 2019-09-03 | Vactronix Scientific, Llc | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US9107605B2 (en) | 2000-11-17 | 2015-08-18 | Advanced Bio Prosthetic Surfaces, Ltd., A Wholly Owned Subsidiary Of Palmaz Scientific, Inc. | Device for in vivo delivery of bioactive agents and method of manufacture thereof |
US6641607B1 (en) | 2000-12-29 | 2003-11-04 | Advanced Cardiovascular Systems, Inc. | Double tube stent |
US6752829B2 (en) | 2001-01-30 | 2004-06-22 | Scimed Life Systems, Inc. | Stent with channel(s) for containing and delivering a biologically active material and method for manufacturing the same |
US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
US6764505B1 (en) * | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US9216239B2 (en) | 2001-06-08 | 2015-12-22 | Leo Rubin | Medical device for intra-lumenal delivery of pharmaceutical agents |
DE60120955T3 (de) | 2001-07-20 | 2015-06-25 | Cid S.P.A. | Stent |
AU2002322719A1 (en) | 2001-07-26 | 2003-02-17 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US20060224234A1 (en) | 2001-08-29 | 2006-10-05 | Swaminathan Jayaraman | Drug eluting structurally variable stent |
US20060004437A1 (en) | 2001-08-29 | 2006-01-05 | Swaminathan Jayaraman | Structurally variable stents |
TWI233811B (en) | 2001-09-25 | 2005-06-11 | Ind Tech Res Inst | Sustained release micro-porous hollow fiber and method of manufacturing the same |
EP1310242A1 (en) | 2001-11-13 | 2003-05-14 | SORIN BIOMEDICA CARDIO S.p.A. | Carrier and kit for endoluminal delivery of active principles |
US7014654B2 (en) | 2001-11-30 | 2006-03-21 | Scimed Life Systems, Inc. | Stent designed for the delivery of therapeutic substance or other agents |
US6939374B2 (en) | 2001-12-21 | 2005-09-06 | Scimed Life Systems, Inc. | Stents, stenting systems, and related methods for agent delivery |
EP1348402A1 (en) | 2002-03-29 | 2003-10-01 | Advanced Laser Applications Holding S.A. | Intraluminal endoprosthesis, radially expandable, perforated for drug delivery |
US7122048B2 (en) * | 2002-05-03 | 2006-10-17 | Scimed Life Systems, Inc. | Hypotube endoluminal device |
US20040133270A1 (en) | 2002-07-08 | 2004-07-08 | Axel Grandt | Drug eluting stent and methods of manufacture |
US7044965B1 (en) | 2002-12-13 | 2006-05-16 | Spielberg Theodore E | Therapeutic cellular stent |
US20040147998A1 (en) | 2003-01-24 | 2004-07-29 | Nolting John E. | Differentially coated stent |
US7458985B2 (en) | 2003-01-27 | 2008-12-02 | Frank Madda | Spiral stent assembly |
DE60309281T3 (de) * | 2003-02-10 | 2013-12-12 | Heraeus Precious Metals Gmbh & Co. Kg | Verbesserte Metalllegierung für medizinische Geräte und Implantate |
US7182735B2 (en) | 2003-02-26 | 2007-02-27 | Scimed Life Systems, Inc. | Elongated intracorporal medical device |
EP1610823B1 (en) | 2003-03-28 | 2011-09-28 | Innovational Holdings, LLC | Implantable medical device with continuous agent concentration gradient |
US20050070996A1 (en) | 2003-04-08 | 2005-03-31 | Dinh Thomas Q. | Drug-eluting stent for controlled drug delivery |
US7104130B2 (en) * | 2003-04-11 | 2006-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Ultra-miniature accelerometers |
US7288084B2 (en) | 2003-04-28 | 2007-10-30 | Boston Scientific Scimed, Inc. | Drug-loaded medical device |
US20050043783A1 (en) | 2003-06-09 | 2005-02-24 | Amis James Peter | Helical endoluminal stent and related methods |
JP2007502135A (ja) | 2003-08-14 | 2007-02-08 | ブルー・メディカル・デバイシーズ・ベスローテン・フェンノートシャップ | 治療剤を含んで成る腔内人工器官 |
US20050055080A1 (en) | 2003-09-05 | 2005-03-10 | Naim Istephanous | Modulated stents and methods of making the stents |
US20050060020A1 (en) | 2003-09-17 | 2005-03-17 | Scimed Life Systems, Inc. | Covered stent with biologically active material |
US7020947B2 (en) | 2003-09-23 | 2006-04-04 | Fort Wayne Metals Research Products Corporation | Metal wire with filaments for biomedical applications |
US9278015B2 (en) | 2003-10-16 | 2016-03-08 | Minvasys | Catheter system for stenting and drug treatment of bifurcated vessels |
CN2664617Y (zh) * | 2003-11-13 | 2004-12-22 | 美国宙迪公司 | 人体管道内腔支架 |
US7744644B2 (en) | 2004-03-19 | 2010-06-29 | Boston Scientific Scimed, Inc. | Medical articles having regions with polyelectrolyte multilayer coatings for regulating drug release |
US7989490B2 (en) | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
EP1600534A1 (en) | 2004-05-27 | 2005-11-30 | Shenzhen Yang Qian Material Application Technology Co., Ltd. | Process of manufacturing core-sheath composite fiber |
US8323333B2 (en) | 2005-03-03 | 2012-12-04 | Icon Medical Corp. | Fragile structure protective coating |
WO2007021749A1 (en) | 2005-08-10 | 2007-02-22 | Med Institute, Inc. | Intraluminal device with a hollow structure |
US20070055352A1 (en) | 2005-09-07 | 2007-03-08 | Wendy Naimark | Stent with pockets for containing a therapeutic agent |
GB0522569D0 (en) | 2005-11-04 | 2005-12-14 | Univ Bath | Biocompatible drug delivery device |
US20070168021A1 (en) | 2006-01-17 | 2007-07-19 | Holmes David R Jr | Porous three dimensional nest scaffolding |
US20070173923A1 (en) | 2006-01-20 | 2007-07-26 | Savage Douglas R | Drug reservoir stent |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
US9198749B2 (en) | 2006-10-12 | 2015-12-01 | C. R. Bard, Inc. | Vascular grafts with multiple channels and methods for making |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US7575593B2 (en) | 2007-01-30 | 2009-08-18 | Medtronic Vascular, Inc. | Implantable device with reservoirs for increased drug loading |
US8221496B2 (en) | 2007-02-01 | 2012-07-17 | Cordis Corporation | Antithrombotic and anti-restenotic drug eluting stent |
WO2008098926A1 (en) | 2007-02-13 | 2008-08-21 | Cinvention Ag | Reservoir implants and stents |
WO2008098924A2 (en) | 2007-02-13 | 2008-08-21 | Cinvention Ag | Medical devices with extended or multiple reservoirs |
US20080234809A1 (en) | 2007-03-23 | 2008-09-25 | Medtronic Vascular, Inc. | Stent Graft System With Injection Tube |
US20080249599A1 (en) | 2007-04-05 | 2008-10-09 | Medtronic Vascular, Inc. | Stent With Therapeutic Agent Delivery Structures in Low Strain Regions |
TW200840553A (en) | 2007-04-12 | 2008-10-16 | Jung-Tang Huang | A fabrication method for drug-eluting stent with medicine-compatible filling mechanism |
US8328867B2 (en) | 2007-06-08 | 2012-12-11 | Medtronic Vascular, Inc. | Drug loaded implantable medical device |
US20090024209A1 (en) | 2007-07-20 | 2009-01-22 | Medtronic Vascular, Inc. | Hypotubes for Intravascular Drug Delivery |
DE102007034041A1 (de) * | 2007-07-20 | 2009-01-22 | Biotronik Vi Patent Ag | Medikamentendepots für medizinische Implantate |
US20090035351A1 (en) | 2007-07-20 | 2009-02-05 | Medtronic Vascular, Inc. | Bioabsorbable Hypotubes for Intravascular Drug Delivery |
US20090157172A1 (en) | 2007-07-24 | 2009-06-18 | Boston Scientific Scrimed, Inc. | Stents with polymer-free coatings for delivering a therapeutic agent |
US7901726B2 (en) | 2007-08-31 | 2011-03-08 | Boston Scientific Scimed, Inc. | Porous medical articles for therapeutic agent delivery |
US20090076591A1 (en) * | 2007-09-19 | 2009-03-19 | Boston Scientific Scimed, Inc. | Stent Design Allowing Extended Release of Drug and/or Enhanced Adhesion of Polymer to OD Surface |
US20090093871A1 (en) * | 2007-10-08 | 2009-04-09 | Medtronic Vascular, Inc. | Medical Implant With Internal Drug Delivery System |
US8016880B2 (en) | 2007-11-16 | 2011-09-13 | Medtronic Vascular, Inc. | Stent having spiral channel for drug delivery |
ES2371380T3 (es) * | 2008-01-24 | 2011-12-30 | Boston Scientific Scimed, Inc. | Stent para suministrar un agente terapéutico desde una superficie lateral de un vástago de stent. |
US8114151B2 (en) | 2008-05-08 | 2012-02-14 | Boston Scientific Scimed, Inc. | Stent with tabs and holes for drug delivery |
DE102008002397A1 (de) | 2008-06-12 | 2009-12-17 | Biotronik Vi Patent Ag | Implantierbare Vorrichtung |
US20090319026A1 (en) | 2008-06-20 | 2009-12-24 | Boston Scientific Scimed, Inc. | Composite Stent with Reservoirs for Drug Delivery and Methods of Manufacturing |
DE102008040356A1 (de) | 2008-07-11 | 2010-01-14 | Biotronik Vi Patent Ag | Stent mit biodegradierbaren Stentstreben und Wirkstoffdepots |
US7951193B2 (en) * | 2008-07-23 | 2011-05-31 | Boston Scientific Scimed, Inc. | Drug-eluting stent |
US20100036482A1 (en) | 2008-08-07 | 2010-02-11 | Exogenesis Corporation | Drug delivery system and method of manufacturing thereof |
WO2010030873A1 (en) * | 2008-09-12 | 2010-03-18 | Boston Scientific Scimed, Inc. | Layer by layer manufacturing of a stent |
US20100082096A1 (en) | 2008-09-30 | 2010-04-01 | Boston Scientific Scimed, Inc. | Tailored Luminal & Abluminal Drug Elution |
-
2010
- 2010-09-17 US US12/884,343 patent/US8333801B2/en active Active
-
2011
- 2011-08-30 WO PCT/US2011/049761 patent/WO2012036890A1/en active Application Filing
- 2011-08-30 JP JP2013529177A patent/JP5895325B2/ja active Active
- 2011-08-30 EP EP11752731.7A patent/EP2616110B1/en active Active
- 2011-08-30 CN CN201180044263.7A patent/CN103249437B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103249437B (zh) | 2016-09-21 |
WO2012036890A1 (en) | 2012-03-22 |
US8333801B2 (en) | 2012-12-18 |
CN103249437A (zh) | 2013-08-14 |
EP2616110B1 (en) | 2016-07-20 |
JP2013541971A (ja) | 2013-11-21 |
US20120067008A1 (en) | 2012-03-22 |
EP2616110A1 (en) | 2013-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5895325B2 (ja) | 薬剤溶出型医療器具の作成方法 | |
JP5895324B2 (ja) | 薬剤溶出型医療器具の作成方法 | |
US10632004B2 (en) | Hollow drug-filled stent and method of forming hollow drug-filled stent | |
CN106963525B (zh) | 空心药物填充支架和形成该空心药物填充支架的方法 | |
JP6748674B2 (ja) | ニチノールステントを形成する方法 | |
US10137016B2 (en) | Hollow drug-filled stent and method of forming hollow drug-filled stent | |
CN109922760B (zh) | 用于防止血管微损伤的药物填充支架及其制造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140829 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150702 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150708 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151008 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160212 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5895325 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |